Aspirin and colorectal cancer prevention: what the CAPP2 trial found
Aspirin is one of the oldest drugs in widespread use. Most people think of it as a painkiller, or something cardiologists recommend in low doses to reduce heart attack risk. Far fewer people know that aspirin has one of the most robust cancer-prevention signals in the entire pharmacological literature — and that this signal is backed by a large, well-designed randomised controlled trial.
This post is about what that trial found, who it applies to, and what the evidence means for anyone thinking about colorectal cancer prevention.
The CAPP2 trial: what it was and what it found
The Colorectal Adenoma/Carcinoma Prevention Programme 2 — known as CAPP2 — was a landmark randomised controlled trial that enrolled 861 carriers of Lynch syndrome across multiple centres in the UK, Europe, and elsewhere. Lynch syndrome is a hereditary condition caused by mutations in DNA mismatch repair genes, which gives carriers a substantially elevated lifetime risk of colorectal cancer (up to 80% in some gene variants) as well as increased risk of endometrial, ovarian, and other cancers.
Participants were randomised to receive either 600 mg aspirin per day or placebo, and followed for a mean of 29 months on the intervention. Long-term follow-up data, published in the Lancet in 2011 and updated in subsequent analyses, tracked outcomes for years after the trial ended.
The primary finding was striking. Over the short intervention period, aspirin showed no significant effect on colorectal cancer incidence. But in the longer-term follow-up — at a mean of over four years after randomisation — carriers who had taken aspirin had a 41% reduction in colorectal cancer incidence compared to those who had taken placebo. A further updated analysis extending follow-up to over ten years confirmed this protective effect was sustained.
This delayed protective effect is biologically important. Aspirin does not prevent cancer by blocking a tumour that is already forming — it appears to act upstream, suppressing the inflammatory and proliferative pathways that drive early colorectal carcinogenesis. That process takes time to manifest as a measurable difference in cancer incidence.
How aspirin works in colorectal cancer biology
Aspirin inhibits cyclo-oxygenase enzymes — COX-1 and COX-2 — which are central to the production of prostaglandins, signalling molecules that promote inflammation, cell proliferation, and the suppression of apoptosis (programmed cell death). COX-2 is frequently overexpressed in colorectal cancer and in colorectal adenomas — the precancerous polyps that precede most colorectal cancers.
By inhibiting COX-2 activity, aspirin appears to reduce prostaglandin-driven proliferation, increase apoptosis in abnormal cells, and potentially slow the progression of adenomas to carcinoma. There is also evidence that aspirin modulates DNA mismatch repair pathways — particularly relevant in Lynch syndrome, where these pathways are already compromised.
This is one of the cleaner mechanism-to-outcome stories in cancer prevention pharmacology: a plausible biological mechanism, supported by a large randomised trial with long-term follow-up, showing a clinically meaningful effect.
Does this apply beyond Lynch syndrome?
The CAPP2 trial was conducted specifically in Lynch syndrome carriers — a high-risk population with a known genetic predisposition to colorectal cancer. The question of whether aspirin’s protective effect extends to the general population is important and only partially answered.
Observational evidence is encouraging. Multiple large prospective cohort studies — including analyses from the Nurses’ Health Study and the Health Professionals Follow-up Study — have found that regular aspirin use is associated with a 20–30% reduction in colorectal cancer risk in the general population. A systematic comparison of observational versus randomised trial evidence, published in Lancet Oncology in 2012, found that the consistency of the aspirin-cancer signal across both study types strengthens the case for a genuine causal effect.
However, the general population evidence is primarily observational — not from randomised trials of the same scale as CAPP2. And the risk-benefit calculation in the general population is more complicated, because the baseline colorectal cancer risk is much lower, whilst the risks of aspirin — principally gastrointestinal bleeding and, at higher doses, haemorrhagic stroke — remain constant.
The colorectal cancer and nutrition review published in Nutrients in 2019, synthesising dietary and pharmacological approaches to colorectal cancer prevention, noted aspirin as one of the most evidence-supported preventive interventions alongside dietary fibre, physical activity, and dairy intake — whilst emphasising the importance of individual risk assessment before recommending it.
What this means in practice
If you have Lynch syndrome or a strong family history of colorectal cancer, aspirin is worth a serious conversation with your gastroenterologist or oncologist. The CAPP2 evidence is among the strongest in cancer chemoprevention — a 41% reduction in colorectal cancer incidence from a cheap, widely available drug is a clinically significant finding. Current guidance in the UK recommends aspirin for Lynch syndrome carriers in many cases, alongside regular colonoscopic surveillance.
If you are at average or moderately elevated colorectal cancer risk, the aspirin question is more nuanced. The observational evidence is consistent, but the decision requires weighing your individual colorectal cancer risk against your personal bleeding risk. Factors that increase aspirin’s gastrointestinal bleeding risk include a history of peptic ulcer disease, concurrent NSAID use, heavy alcohol consumption, and certain medications. This is a conversation to have with your GP, not a self-prescribing decision.
Diet remains the foundation. Aspirin does not substitute for the dietary and lifestyle factors with the broadest, most replicated evidence base. High dietary fibre — from whole grains, legumes, vegetables, and fruit — is consistently associated with reduced colorectal cancer risk across multiple study types. Physical activity, healthy body weight, limiting red and processed meat, and minimising alcohol all contribute independently. Aspirin, if appropriate, adds to this foundation rather than replacing it.
Dose matters. The CAPP2 trial used 600 mg daily — a higher dose than the 75–100 mg low-dose aspirin used for cardiovascular prevention. Whether lower doses produce equivalent cancer-preventive effects is still being investigated; the CAPP3 trial is currently examining different dose regimens in Lynch syndrome carriers. Do not self-prescribe high-dose aspirin without medical guidance.
What the evidence does not show
CAPP2 does not tell us that aspirin prevents colorectal cancer in average-risk individuals. The trial was conducted in a high-risk genetic population, and the absolute risk reduction — whilst proportionally impressive — reflects a population whose baseline risk was substantially higher than that of the general population.
The evidence does not yet establish the optimal dose, duration, or starting age for aspirin as a cancer preventive. These are active research questions, and guidance may evolve as trials like CAPP3 report their findings.
And aspirin does not protect against the full range of colorectal cancer risk factors. It appears to act primarily on the inflammatory and proliferative pathways driven by COX-2. It does not reverse the effects of a low-fibre diet, obesity, or physical inactivity on colorectal cancer risk.
The bottom line
Aspirin has one of the most compelling cancer-prevention evidence bases of any pharmacological agent — a 41% reduction in colorectal cancer incidence in Lynch syndrome carriers over long-term follow-up, with a plausible and well-characterised biological mechanism. For high-risk individuals, it warrants serious clinical discussion. For the general population, the observational evidence is consistent but the individual risk-benefit calculation is more complex. Aspirin is not a substitute for the diet, exercise, and lifestyle factors with the broadest evidence base — but it is a serious tool in cancer prevention, and one most people have never heard discussed in this context.
Scientific references
- Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–2087. PMID: 22036019. DOI: 10.1016/S0140-6736(11)61049-0
- Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncology. 2012;13(5):518–527. PMID: 22440112. DOI: 10.1016/S1470-2045(12)70112-2
- Song M, Chan AT. Environmental factors, gut microbiota, and colorectal cancer prevention. Clinical Gastroenterology and Hepatology. 2019;17(2):275–289. PMID: 30243796. DOI: 10.1016/j.cgh.2018.07.012
- Turati F, et al. Colorectal cancer and nutrition. Nutrients. 2019. PMID: 30646512
- Patel AV, et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians. 2020;70(4):245–271. DOI: 10.3322/caac.21591
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
